Comparison of elderly and young onset rheumatoid arthritis

Objective: To describe demographic, clinical, paraclinical and therapeutic characteristics of elderly onset (EORA) compared to young-onset (YORA) rheumatoid arthritis. Patients and Methods: We studied 50 EORA and 100 YORA. Socio-demographic characteristics, clinical and paraclinical data of the dis...

Full description

Bibliographic Details
Main Authors: N. Jaouad, B. Amine, I. Elbinoune, S. Rostom, R. Bahiri
Format: Article
Language:English
Published: Verduci Editore 2022-12-01
Series:Beyond Rheumatology
Subjects:
Online Access:https://www.beyond-rheumatology.org/wp-content/uploads/sites/10/2022/12/e445.pdf
_version_ 1797831380480032768
author N. Jaouad
B. Amine
I. Elbinoune
S. Rostom
R. Bahiri
author_facet N. Jaouad
B. Amine
I. Elbinoune
S. Rostom
R. Bahiri
author_sort N. Jaouad
collection DOAJ
description Objective: To describe demographic, clinical, paraclinical and therapeutic characteristics of elderly onset (EORA) compared to young-onset (YORA) rheumatoid arthritis. Patients and Methods: We studied 50 EORA and 100 YORA. Socio-demographic characteristics, clinical and paraclinical data of the disease were collected as well as the treatments assigned to patients. EORA patients were defined as disease onset ≥ 60 years. Results: At the study visit, EORA patients had a mean age of 68.3 ± 6.4 years old and YORA patients were aged 42.5 ± 9.1 years old. A male predominance was noted in EORA group than the YORA group (38% vs. 12%, p <0.001). The onset of disease in EORA was more acute (p <0.001) with more systemic symptoms (p <0.001). EORA patients had higher Disease Activity Score of 28 joints (DAS28) (p=0.03) and higher erythrocyte sedimentation rate (ESR) (40 [10-110] vs. 28 [2-88], p=0.015). There was no significant difference in seropositive character, prevalence of radiographic erosions or joint deformity. The EORA patients had a higher Health Assessment Questionnaire (HAQ) (1 [0.4-2.2] vs. 0.6 [0.2-2], p<0.001) and more comorbidities (84% vs. 37%, p<0.001). Methotrexate was the most conventional synthetic disease-modifying antirheumatic drugs used in the two groups (95% in the YORA and 96% in the EORA; p=0.740). The EORA group received fewer biologic drugs than the YORA group (30% vs. 47 %; p=0.041). Conclusions: There were more male in EORA group. Activity and HAQ was higher in the EORA group. The EORA had more comorbidities which may explain the lesser use of biological treatments.
first_indexed 2024-04-09T13:51:23Z
format Article
id doaj.art-269395aed2df48829efdd06627bd95d9
institution Directory Open Access Journal
issn 2612-5110
language English
last_indexed 2024-04-09T13:51:23Z
publishDate 2022-12-01
publisher Verduci Editore
record_format Article
series Beyond Rheumatology
spelling doaj.art-269395aed2df48829efdd06627bd95d92023-05-08T14:41:26ZengVerduci EditoreBeyond Rheumatology2612-51102022-12-01410.53238/br_202212_445445Comparison of elderly and young onset rheumatoid arthritisN. Jaouad0B. Amine1I. Elbinoune2S. Rostom3R. Bahiri4Department of Rheumatology A, El Ayachi Hospital, Ibn Sina University Hospital, Salé, MoroccoDepartment of Rheumatology A, El Ayachi Hospital, Ibn Sina University Hospital, Salé, MoroccoDepartment of Rheumatology A, El Ayachi Hospital, Ibn Sina University Hospital, Salé, MoroccoDepartment of Rheumatology A, El Ayachi Hospital, Ibn Sina University Hospital, Salé, MoroccoDepartment of Rheumatology A, El Ayachi Hospital, Ibn Sina University Hospital, Salé, MoroccoObjective: To describe demographic, clinical, paraclinical and therapeutic characteristics of elderly onset (EORA) compared to young-onset (YORA) rheumatoid arthritis. Patients and Methods: We studied 50 EORA and 100 YORA. Socio-demographic characteristics, clinical and paraclinical data of the disease were collected as well as the treatments assigned to patients. EORA patients were defined as disease onset ≥ 60 years. Results: At the study visit, EORA patients had a mean age of 68.3 ± 6.4 years old and YORA patients were aged 42.5 ± 9.1 years old. A male predominance was noted in EORA group than the YORA group (38% vs. 12%, p <0.001). The onset of disease in EORA was more acute (p <0.001) with more systemic symptoms (p <0.001). EORA patients had higher Disease Activity Score of 28 joints (DAS28) (p=0.03) and higher erythrocyte sedimentation rate (ESR) (40 [10-110] vs. 28 [2-88], p=0.015). There was no significant difference in seropositive character, prevalence of radiographic erosions or joint deformity. The EORA patients had a higher Health Assessment Questionnaire (HAQ) (1 [0.4-2.2] vs. 0.6 [0.2-2], p<0.001) and more comorbidities (84% vs. 37%, p<0.001). Methotrexate was the most conventional synthetic disease-modifying antirheumatic drugs used in the two groups (95% in the YORA and 96% in the EORA; p=0.740). The EORA group received fewer biologic drugs than the YORA group (30% vs. 47 %; p=0.041). Conclusions: There were more male in EORA group. Activity and HAQ was higher in the EORA group. The EORA had more comorbidities which may explain the lesser use of biological treatments.https://www.beyond-rheumatology.org/wp-content/uploads/sites/10/2022/12/e445.pdfrheumatoid arthritiselderly onsetyoung-onsetdisease activitylife qualitycomorbiditiesdisease modifying antirheumatic drugs
spellingShingle N. Jaouad
B. Amine
I. Elbinoune
S. Rostom
R. Bahiri
Comparison of elderly and young onset rheumatoid arthritis
Beyond Rheumatology
rheumatoid arthritis
elderly onset
young-onset
disease activity
life quality
comorbidities
disease modifying antirheumatic drugs
title Comparison of elderly and young onset rheumatoid arthritis
title_full Comparison of elderly and young onset rheumatoid arthritis
title_fullStr Comparison of elderly and young onset rheumatoid arthritis
title_full_unstemmed Comparison of elderly and young onset rheumatoid arthritis
title_short Comparison of elderly and young onset rheumatoid arthritis
title_sort comparison of elderly and young onset rheumatoid arthritis
topic rheumatoid arthritis
elderly onset
young-onset
disease activity
life quality
comorbidities
disease modifying antirheumatic drugs
url https://www.beyond-rheumatology.org/wp-content/uploads/sites/10/2022/12/e445.pdf
work_keys_str_mv AT njaouad comparisonofelderlyandyoungonsetrheumatoidarthritis
AT bamine comparisonofelderlyandyoungonsetrheumatoidarthritis
AT ielbinoune comparisonofelderlyandyoungonsetrheumatoidarthritis
AT srostom comparisonofelderlyandyoungonsetrheumatoidarthritis
AT rbahiri comparisonofelderlyandyoungonsetrheumatoidarthritis